Here's a continuation of the webinar content by Dr. Lecia Sequist, who is an Assistant Professor of Medicine at Harvard Medical School and Massachusetts General Hospital (MGH).

A topic that came up in a recent expert round table case discussion was the issue of how to manage a patient with a lung cancer for which the pathology report says "NSCLC not otherwise specified (NOS)", or "poorly differentiated NSCLC, NOS". What does this actually mean, and what does it mean in terms of treatment options?

This is the first of the presentations by guest speakers at our NSCLC Patient Education Forum back in September. Dr. Gerard Silvestri is a pulmonologist, a lung disease specialist (not only cancer), and he is also one of the most important leaders in lung cancer within the field of pulmonology, as both a writer of some very important work and as a great speaker.

Have you ever wondered how exactly your oncologist knew what kind of cancer you had when he/she told you or a loved one about your diagnosis, whether it was non-small cell lung cancer (such as squamous cell or adenocarcinoma), breast cancer, or colon cancer?